Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer
Chief of Division of Hematology and Medical Oncology at shared a post on LinkedIn about a paper titled “Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial” published in The Lancet Oncology.
Authors: Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim.
“Trastuzumab deruxtecan therapy improved patient reported outcomes in patients with HER2-positive metastatic breast cancer who progressed after receiving trastuzumab-DM1. A recent update from the DESTINY Breast02 trial confirms trastuzumab deruxtecan as the best option for this population.
Fehm T, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer, DESTINY-Breast02: patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology 2024.”
